Tfh Cells Potential Dual Role in Cancer: A Perspective

Published: Jan. 1, 2024

Language: Английский

---

Tfh Cells Potential Dual Role in Cancer: A Perspective

Heliyon, Journal Year: 2024, Volume and Issue: 10(19), P. e37502 - e37502

Published: Sept. 12, 2024

Language: Английский

---

Clonal evolution and relapse in early‐stage follicular lymphoma – a tree with many branches^†

The Journal of Pathology, Journal Year: 2024, Volume and Issue: 263(3), P. 271 - 274

Published: May 22, 2024

Abstract Follicular lymphoma (FL) is an indolent B‐cell neoplasm characterised by multistep evolution from premalignant precursor cells carrying the hallmark t(14;18) translocation in majority of cases. In a new article The Journal Pathology , samples relapsed early‐stage FL – primary manifestation and relapse with or without transformation initially treated radiotherapy only, were studied for clonal relationships evolution. Using somatic mutations rearranged immunoglobulin sequences as markers, paired showed so‐called branched common, possibly progenitor cell, both shared private mutations. addition, clonally unrelated cases identified. This previous studies similar findings clearly document that many instances not necessarily represents linear progression disease due to acquisition additional therapy resistance, but rather outgrowths derived pool related, long‐lived, low proliferating cells, even second neoplasms. © 2024 Authors. published John Wiley & Sons Ltd on behalf Pathological Society Great Britain Ireland.

Language: Английский

---

The landscape of T-cell engagers for the treatment of follicular lymphoma

OncoImmunology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Oct. 8, 2024

Follicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival progression. Despite initial responsiveness to chemoimmunotherapy, FL is generally considered incurable. Strategies improve immune-mediated control could significantly benefit this population, particularly as it includes many elderly comorbid patients. Immune cell engagers, especially bispecific antibodies (BsAbs), are crucial targeting by bridging effector thereby triggering T-cell activation cytotoxic killing. CD3 × CD20 BsAbs have shown promise clinical development B-NHL patients, structural variations affecting their target affinity potency. This review summarizes current trials relapsed/refractory FL, highlighting approval some agents, role first-line treatment or combination therapies, toxicity profiles, future therapeutic approach compared other therapies.

Language: Английский

---

A phase 2 study of frontline pembrolizumab in follicular lymphoma

eJHaem, Journal Year: 2024, Volume and Issue: 5(6), P. 1173 - 1181

Published: Oct. 10, 2024

Abstract Background The tumor microenvironment (TME), including infiltrating T‐cells, is thought to play a major role in the pathogenesis and prognosis of follicular lymphoma (FL) may contribute its widely varied disease course. We hypothesized that programmed death‐1 inhibition be most effective untreated, immunocompetent FL patients. Thus, we developed phase 2 study evaluate efficacy pembrolizumab as initial treatment for indolent B‐cell lymphoma. Methods Adults with or marginal zone an indication were eligible. Patients received 200 mg IV 21‐day cycles up 18 cycles, until progression unacceptable toxicity. Early response assessment was obtained after cycle 3 computed tomography (CT), fluorodeoxyglucose (FDG)‐positron emission tomography‐computed (PET‐CT) 6 determine candidacy continuation study. Immunosecretome profiling performed at baseline on day 1. Results Nine patients enrolled between February 2019 April 2021, eight (89%) advanced stage, seven (78%) intermediate/high Follicular Lymphoma International Prognostic Index, six (67%) high‐tumor burden by Groupe d'Etude des Lymphomes Folliculaires. best overall rate FDG PET‐CT 33% (three partial metabolic responses). Three (33%) had stable disease, three progressive (including one patient who only follow‐up CT). By CT four (44%) experienced reduction target lesions, but all less than responses. Grade higher immune‐related adverse events (IRAEs) seen two (22%) patients, both transaminitis whom concurrent hypophysitis. Another grade 1 pneumonitis, requiring steroids. No associations immunosecretome profile clinical outcomes could detected. Conclusion Frontline associated limited responses clinically significant IRAEs. Alternative strategies targeting TME should explored.

Language: Английский

---

Spatially Variable Genes

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 28

Published: Dec. 17, 2024

The clinical translation of spatial transcriptomics represents cancer diagnosis and therapy based on the role heterogeneity cancer-associated fibroblasts (CAFs) within tumor microenvironment (TME). Recent developments in have enabled a detailed characterization organization cellular interactions tumors. data integration, multi-omics approaches, along with developing standardized protocols is essential for effective translation. experimental selection regimes factorial designs reveals novel insights into biomarkers prognostic value CAFs. incorporation optogenetics advancements bio-engineered gene circuits, therapeutics tissue engineering further underscores potential to refine patient stratification improve treatment responsiveness. By integrating workflows, this work aims advance personalized therapies biology.

Language: Английский

---